Search
Research
Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of ageFood allergy is a major public health challenge in Australia. Despite widespread uptake of infant feeding and allergy prevention guidelines the incidence of peanut allergy in infants has not fallen, and prevalence of peanut allergy in school-aged children continues to rise. Therefore, effective and accessible treatments for peanut allergy are required.
Research
Increasing emergency department visits for anaphylaxis in very early childhood: A canary in the coal mineThe incidence of anaphylaxis is increasing globally in tandem with changing environmental and lifestyle factors. There is very limited data on very early childhood presentations. We aim to assess changes in rates, characteristics and management of infant anaphylaxis in a paediatric ED over a 15-year period.
Research
T-cell activation genes differentially expressed at birth in CD4+ T-cells from children who develop IgE food allergyTo show underlying mechanisms, we examined differences in T-cell gene expression in samples at birth and at 1 year in children with and without IgE allergy.
Research
The relationship between maternal folate status in pregnancy, cord blood folate levels, and allergic outcomes in early childhoodThis study examined whether maternal and/or fetal folate status in pregnancy is associated with infant allergic outcomes.
Research
Gene polymorphisms, breast-feeding, and development of food sensitization in early childhoodThe effect of breast-feeding on the development of allergic disease is uncertain
Research
Does genetic regulation of IgE begin in utero?Elucidation of early life factors is critical to understand the development of allergic diseases, especially those manifesting in early life such as food allerg
Research
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trialOral immunotherapy is effective at inducing desensitisation to allergens and induces sustained unresponsiveness (ie, clinical remission) in a subset of patients, but causes frequent reactions. We aimed to investigate whether addition of a probiotic adjuvant improved the efficacy or safety of peanut oral immunotherapy.
Research
Identifying gene network patterns and associated cellular immune responses in children with or without nut allergyAlthough evidence suggests that the immune system plays a key role in the pathophysiology of nut allergy, the precise immunological mechanisms of nut allergy have not been systematically investigated. The aim of the present study was to identify gene network patterns and associated cellular immune responses in children with or without nut allergy.
Research
Dysfunctional gut microbiome networks in childhood ige‐mediated food allergyThe development of food allergy has been reported to be related with the changes in the gut microbiome, however the specific microbe associated with the pathogenesis of food allergy remains elusive. This study aimed to comprehensively characterize the gut microbiome and identify individual or group gut microbes relating to food-allergy using 16S rRNA gene sequencing with network analysis.
Research
Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapyPeanut allergy is the the most common cause of life-threatening food-induced anaphylaxis. There is currently no effective long-term treatment. There is a pressing need for definitive treatments that improve the quality of life and prevent fatalities. Allergen oral immunotherapy (OIT) is a promising approach, which is effective at inducing desensitisation; however, OIT has a limited ability to induce sustained unresponsiveness (SU).